Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck settles with IRS

Executive Summary

Merck will pay approximately $2.3 billion to the Internal Revenue Service to settle tax disputes from 1993 to 2001, the firm reports Feb. 14. The agreement covers federal tax, net interest after federal tax deductions and penalties. Merck previously estimated its liability for four investigations of the company's tax returns at $5.58 billion plus penalties (1"The Pink Sheet" Nov. 13, 2006, p. 10). The settlement adds to IRS' momentum in its effort to collect taxes that pharma companies have sheltered through offshore income shifting (2"The Pink Sheet" Aug. 14, 2006, p. 7)...

You may also be interested in...



Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability

U.S. Drug Firms Under IRS Scrutiny For Offshore Income Shifting

U.S.-based drug companies inappropriately reported that foreign profits accounted for 66% of their worldwide profits in 2003-2005, 23% more than the amount calculated by Tax Analysts, according to a publication by the non-profit group

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel